TY - JOUR T1 - R-Scale for Pulmonary Fibrosis (PF): a simple, visual tool for the assessment of health-related quality of life JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00917-2021 SP - 2100917 AU - Ciaran Scallan AU - Lauren Strand AU - Jennifer Hayes AU - Suha Kadura AU - Bridget Collins AU - Lawrence Ho AU - Carolyn Spada AU - Will Canestaro AU - Martin Kolb AU - Ganesh Raghu Y1 - 2021/01/01 UR - http://erj.ersjournals.com/content/early/2021/05/28/13993003.00917-2021.abstract N2 - Rationale Patients with Idiopathic Pulmonary Fibrosis (IPF) experience impaired health related quality of life (HRQoL). Several tools have been developed to objectively assess HRQoL in this patient population, but none are in use in routine clinical practice.Objectives To develop a rapid, specific tool that can be used for patients with IPF during routine clinic visits.Methods A novel and simple 5-item numerical rating scale (NRS) was developed and compared with two other previously validated tools. 100 consecutive patients with IPF managed at the center for ILD, were recruited to complete the R-Scale-PF, the Kings Brief Interstitial Lung Disease Questionnaire (K-BILD), and the EuroQol 5-Dimensional 5-Level Questionnaire (EQ-5D-5 L) in addition to pulmonary function and 6-min walk tests.Measurements and Main Results All 100 patients successfully completed the three HRQoL tools with 53 completing them again at follow up visits. Internal consistency was high (Cronbach's α 0.825) with minimal floor/ceiling effect. Concurrent validity of the R-Scale-PF was moderate to high compared with the K-BILD (r=−0.713) and the EQ-5D-5 L (r=−0.665). Concurrent validity was moderate with physiologic measures (forced vital capacity, r=−0.307, 6-min walk distance, r=−0.383). The R-Scale-PF demonstrated good known-groups validity when comparing scores across stages of disease severity.Conclusions The R-Scale-PF correlates well with the K-BILD and EQ-5D-5 L. It is hoped that this novel simple NRS tool subject to validation in patients from other centers will provide the opportunity to objectively measure HRQoL in routine clinical practice for patients with IPF.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Scallan has nothing to disclose.Conflict of interest: Dr. Strand has nothing to disclose.Conflict of interest: Dr. Hayes has nothing to disclose.Conflict of interest: Dr. Kadura has nothing to disclose.Conflict of interest: Dr. Collins reports personal fees from Boehringer Ingelheim, outside the submitted work; .Conflict of interest: Dr. Ho has nothing to disclose.Conflict of interest: Dr. Spada has nothing to disclose.Conflict of interest: Dr. Canestaro has nothing to disclose.Conflict of interest: Dr. Kolb reports grants from Canadian Pulmonary Fibrosis Foundation, other from Roche, other from Boehringer Ingelheim, grants from Canadian Institute for Health Research, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Roche, grants and personal fees from Liminal, other from European Respiratory Journal, personal fees from Third Pole, personal fees from MitoImmune, grants and personal fees from Pieris, personal fees from Abbvie, personal fees from DevPro Biopharma, personal fees from Horizon, personal fees from Algernon, personal fees from CSL Behring, outside the submitted work; .Conflict of interest: Dr. Raghu has nothing to disclose. ER -